CFMS / ConforMIS (CFMS) Moves to Buy: Rationale Behind the Upgrade

ConforMIS (CFMS) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.56. This compares to loss of $2 more_horizontal

BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee more_horizontal

ConforMIS (CFMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

Conformis, Inc. (NASDAQ:CFMS ) Q4 2022 Results Conference Call March 1, 2023 4:30 PM ET Company Participants Mark Augusti - President and Chief Execut more_horizontal

BILLERICA, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee a more_horizontal

Conformis, Inc. (NASDAQ:CFMS ) Q3 2022 Results Conference Call November 2, 2022 4:30 PM ET Company Participants Mark Augusti - President and CEO Bob H more_horizontal

ConforMIS (CFMS) delivered earnings and revenue surprises of -14.29% and 0.79%, respectively, for the quarter ended September 2022. Do the numbers hol more_horizontal

BILLERICA, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee more_horizontal